An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

  title={An mRNA Vaccine against SARS-CoV-2 — Preliminary Report},
  author={Lisa A. Jackson and Evan J Anderson and Nadine G. Rouphael and Paul C. Roberts and Mamodikoe Makhene and Rhea N Coler and Michele P McCullough and James Chappell and Mark R. Denison and Laura J. Stevens and Andrea J Pruijssers and Adrian B McDermott and Britta Flach and Nicole A Doria-Rose and Kizzmekia S. Corbett and Kaitlyn M. Morabito and Sijy O'Dell and Stephen D. Schmidt and Phillip A Swanson and Marcelino Gonz{\'a}lez Padilla and John R. Mascola and Kathleen M Neuzil and Hamilton Bennett and Wellington Sun and Etza Peters and Mat Makowski and Jim Albert and Kaitlyn Cross and Wendy L Buchanan and Rhonda Pikaart-Tautges and Julie E Ledgerwood and Barney S. Graham and John H Beigel},
  journal={The New England Journal of Medicine},
  • Lisa A. Jackson, Evan J Anderson, +30 authors John H Beigel
  • Published 2020
  • Medicine
  • The New England Journal of Medicine
  • Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. Methods We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg… CONTINUE READING


    Publications citing this paper.

    Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate